The exemption will allow 3Spine to study its Motus device in a clinical trial, according to a June 22 news release. The company finished contracting and site initiation at 16 U.S. centers for a prospective study.
Motus is an implant used in the BalancedBack total joint replacement procedure. It is designed to address leg pain, back pain and spinal instability, 3Spine said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.